Post-Market Data
Real World Evidence
Patients
863
9 reporting clinics
6-month improvement
31
Mean outcome score
Follow-up complete
95%
Across due timepoints
Safety flags
4
Awaiting review
Patient Reported Outcomes
Pain, stiffness, and function · Lower is better · Mean score for 863 patients · 31 point improvement
Patients by clinic
Enrolment in the selected cohort
- Manchester Orthopaedics248
- Berlin Gelenkzentrum173
- Paris Clinique du Mouvement156
- Bristol Joint Centre104
- Hamburg Movement Lab67
- Bordeaux Foot Institute52
- London Sports Clinic31
- Munich Ortho Campus18
- Lyon Outcomes Centre14
Anatomic areas
5 areas · 863 procedures
- Knee605
- Shoulder87
- Ankle82
- Hip69
- Spine20
Procedures by area
Events in the selected cohort
- Knee605
- Shoulder87
- Ankle82
- Hip69
- Spine20
Filters update outcomes, completion, clinic benchmarking, and safety signals together.
Need regulated post-market follow-up too? See our Post Market Surveillance page, or get a quote for one combined programme. If the story includes how a wound looks over time, see photo and video diaries.
What you get
Evidence built for the real world
Multi-site, multi-country
Aggregate data from any number of clinics, hospitals or geographies into a single observational dataset.
100% compliance is possible
Branded, frictionless patient experience with timely reminders - the Citius Arthrosamid programme reached 100% compliance.
Validated PROMs
WOMAC, KOOS, Oxford Knee, EQ-5D, VAS and more - scored automatically and timestamped at every interval.
Live dashboards
Track recruitment, completion rates and headline outcome scores while the study is still running.
Clinician-friendly capture
Anatomical and clinical assessment data captured in seconds at the point of care - not after clinic.
Marketing-ready outputs
Charts, narrative and case studies you can share with KOLs, sales teams and prospective customers.
Case Study
Arthrosamid - Citius Retired Athletes
Contura Orthopaedics programme, live from May 2025.
Patient Watch powers the Citius Retired Athletes Program for Arthrosamid knee osteoarthritis treatment. The result: a38.5-point WOMAC improvement at 4 weeks - the best performing Arthrosamid study globally - with100% patient compliance over 12 months of follow-up.
- •QR-code onboarding straight from the waiting room
- •WOMAC, Oxford Knee, EQ-5D and VAS at baseline, 3, 6, 9 and 12 months
- •Live dashboards for the clinical and commercial teams
Case Study
IBSA and Sinovial - multi-centre knee OA programme
Study Start: May 2026
Patient Watch is supporting IBSA and the Sinovial project with a 100-patient real-world programme across 10 clinicians, capturing theOxford Knee Score andEQ-5D alongside injection and safety data. We are helping the team secure the correctlicensed use of these copyright-protected PROMs (Oxford University Innovation and EuroQol) so governance, publications and commercial use stay compliant.
- •Oxford Knee Score and EQ-5D at programme timepoints, with automated scoring and audit trail
- •Follow-up aligned to the Sinovial schedule: baseline, 2 weeks, 3 months and 6 months
- •Health questionnaire, pain tracking and adverse-event capture for a complete RWE dataset
- •Cohort dashboards and exports for medical, regulatory and market access stakeholders
Ask us about running a licensed PROM programme for your own injection or device rollout.
Case Study
Anika Therapeutics - Cingal real-world outcomes
Programme start: July 2026
Patient Watch is supporting Anika with a UK and Germany real-world programme for Cingal knee osteoarthritis. Up to 100 patients across participating clinicians captureWOMAC at baseline, 3, 6, 9 and 12 months - giving medical affairs and market teams outcome data from real clinics, not just trial sites.
- •WOMAC at five timepoints with automated scoring and SMS or email reminders
- •English and German patient journeys, aligned to each country's programme
- •Clinician caseload views plus sponsor dashboards split by market
- •Exportable cohort data for publications, NHS conversations and post-market follow-up
Ask us about a branded real-world programme for your injection or device portfolio.
Generate evidence that sells
Tell us about the product, indication and timelines and we'll scope a study that delivers usable data.